Hormone · FDA Approved
Sermorelin
FDA-approved
01 · Overview
A synthetic 29-amino acid analog of GHRH corresponding to the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates growth hormone secretion from the anterior pituitary through the GHRH receptor and was used as a diagnostic test for GH deficiency (PMID 18031173).
FDA-approved as Geref (1990 for diagnostic use, 1997 for treatment), but all Geref products are now listed as discontinued in FDA records; current US supply is mainly through compounding.
02 · Research summary & key findings
Previously FDA-approved for diagnostic evaluation and treatment of growth hormone deficiency in children; limited data showed sustained increases in height velocity in some prepubertal children, though gains were smaller than with somatropin (PMID 18031173). In older adults, a closely related GHRH(1-29) analog raised GH and IGF-I and increased lean body mass in men only, while self-reported sleep quality did not change (PMID 9141536).
03 · Regulatory status
Sermorelin has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
04 · Administration routes
- Subcutaneous injection
References
- [1]Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs, 1999. PMID 18031173
- [2]Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women J Clin Endocrinol Metab, 1997. PMID 9141536
Primary literature
- PubMed: "Sermorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Sermorelin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Sermorelin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.